Loading
IMNN-201 is an experimental DNA plasmid cancer vaccine from Imunon, in preclinical development for melanoma.
IMNN-201 is a DNA plasmid cancer vaccine (FixPlas platform) from Imunon. A plasmid DNA vaccine against the tumour-associated antigen Trp2. Its furthest stage is preclinical development, for melanoma. No clinical trial naming it is registered on ClinicalTrials.gov. It has not been shown to work in people.
A plasmid DNA vaccine against the tumour-associated antigen Trp2.
1.IMNN-201 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"IMNN-201" OR ABSTRACT:"IMNN-201") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IMNN-201, not a curated reading list.
Shares Imunon and the tag pipeline.
Shares Imunon and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/